Meeting
2024 ASCO Breakthrough
Circulating tumor DNA analysis in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy followed by surgery.
Authors
Mian Xie
Guangdong Provincial People's Hospital, Guangzhou, China
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Local Disease
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 69)
DOI
10.1200/JCO.2024.42.23_suppl.69
Abstract #
69
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Impact of pathological response and recurrence pattern on the survival of patients who develop recurrence from neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC).
First Author: Chien Huai Chuang
Poster
2018 ASCO Annual Meeting
Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: The potential use of ctDNA monitoring as organ-sparing approach.
First Author: Lifeng Yang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
First Author: yueyun chen
Poster
2023 ASCO Annual Meeting
Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma.
First Author: Shogo Takei